Molecular Imaging: Page 2

The rise of theranostics: Part 2 -- Moving into communities

In part 2 of The Rise of theranostics series, experts weigh in on getting started in prostate cancer theranostics as some private urology, radiation oncology practices, and radiologist groups begin building their abilities.

April 4, 2024

Theranostics with Thomas Hope, MD, University of California, San Francisco (UCSF)

SPECT/CT algorithm predicts heart failure hospitalizations

AI can effectively predict hospitalization for acute heart failure exacerbation in patients undergoing SPECT/CT myocardial perfusion imaging.

April 3, 2024

A visual abstract of the study by the authors. Image courtesy of the Journal of Nuclear Medicine.

SNMMI to tackle Capitol Hill

By AuntMinnie.com staff writers

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) will host its annual Hill Day on April 5 in Washington, DC.

April 3, 2024

PET/MRI may improve diagnosis of Cushing disease

PET/MRI could become the diagnostic method of choice over MRI alone for identifying small pituitary tumors associated with Cushing disease.

March 29, 2024

T1-weighted postgadolinium MR images (A and C) and F-18 FET-PET/MR images (B and D) centered at pituitary before (A and B) and after (C and D) transsphenoidal surgery. This patient with Cushing disease showed clear focal uptake (B) but no clear lesion on previously obtained and accompanying MRI (A). Postoperative tissue analysis did confirm resection of small pituitary adenoma/PitNET, and postoperative F-18 FET-PET showed no residual uptake (D). Image courtesy of the Journal of Nuclear Medicine.

The rise of theranostics: Part 1 -- Gaining momentum

FDA-approved radiopharmaceuticals have energized the field of theranostics. In part 1 of a series, experienced theranostics leaders offer implications of the latest clinical trials, how a theranostics clinic works, and advice for introducing theranostics.

March 26, 2024

Team members from the theranostics clinic under University of Texas Health Science Center at San Antonio's Department of Radiology show one aspect of a Pluvicto infusion treatment. The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. (Photo courtesy of UT Health San Antonio Department of Radiology)

Can cardiac PET/CT ‘revolutionize’ heart care?

PET/CT is poised to become a key tool for imaging the coronary arteries as a clinical imaging exam that can reveal early warning signs of fatal conditions when patients present with symptoms of chest pain.

March 25, 2024

Targeted radiopharmaceuticals offer new hope for longer 'healthspans'

By Mark Crockett, MD

Precision radiopharmaceuticals accurately target tumors while minimizing damage to healthy tissue, presenting an opportunity to extend not just lifespans but “healthspans,” Mark Crockett, MD, explains in this article.

March 15, 2024

Groups aim to standardize nuclear medicine imaging of CV infections

Eleven medical associations have released guidance on the use of PET/CT and SPECT/CT for patients with cardiovascular (CV) infections.

March 15, 2024

Cannabis may influence bowel motility

Physicians, health care providers, and medical staff caring for patients who use cannabis should be familiar with the effects of the drug on gut motility, a recent report advises.

March 11, 2024

Hold off on the Egg McMuffins before GES tests, experts say

Nuclear medicine technologists are being advised that not just any meal works for patients before gastric emptying scintigraphy (GES).

March 7, 2024

IMV: PET scan volumes continue to grow

By Davin Korstjens

The total volume of PET scans increased 10.2% year over year in 2023, according to the newly published IMV 2024 PET Market Summary Report.

March 7, 2024

PET lung scan times could be cut by half

Dynamic PET scans acquired in half the time of normal scans appear clinically feasible for patients with lung lesions.

March 6, 2024

A 60-year-old male patient with clinical suspicion of lung cancer. PET/CT scan showed FDG-avid pulmonary nodules in the upper lobe of the left lung (red arrow), with a size of 2.2 × 1.3 cm, SUVmax of 12.2, Ki-65 min of 0.016 ml/g/min, and Ki-30 min of 0.014 ml/g/min. Surgical pathology confirmed a granulomatous lesion. In addition, PET/CT scan showed many FDG-avid lung nodules in the mediastinum. (A, static PET maximum intensity projection; B, static PET SUV image; C, static PET/CT fusion image; D, dynamic PET Ki-65 min image; E, dynamic PET Ki-30 min image). Image courtesy of EJNMMI Physics.

Page 2 of 593